Reference
European Medicines Agency (EMA). Beovu (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion. Internet Document : 5 Nov 2021. Available from: URL: https://www.ema.europa.eu/en/news-events/whats-new
Rights and permissions
About this article
Cite this article
EMA updates recommendations: IOI with brolucizumab. Reactions Weekly 1882, 1 (2021). https://doi.org/10.1007/s40278-021-05468-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-05468-6